10.14.14
Johnson & Johnson
3Q Revenues: $18.5 billion (+5%)
3Q Earnings: $4.7 billion (+59%)
YTD Revenues: $56.1 billion (+6%)
YTD Earnings: $13.8 billion (+34%)
Comments: Worldwide Pharmaceutical sales were $8.3 billion in the quarter, up 18%, with domestic sales up 33%, international sales up 3%, and a negative currency impact of 1%. Sales were driven by new products OLYSIO/SOVRIAD (simeprevir) for chronic hepatitis C; XARELTO (rivaroxaban), an oral anticoagulant; INVOKANA (canagliflozin) for type 2 diabetes; ZYTIGA (abiraterone acetate), for metastatic, castration-resistant prostate cancer; and IMBRUVICA (ibrutinib) for the treatment of several hematologic malignancies. Additional drivers were STELARA (+47% to $543 million), REMICADE (+5% to $1.8 billion), and INVEGA SUSTENNA/XEPLION (+24% to $403 million).
3Q Revenues: $18.5 billion (+5%)
3Q Earnings: $4.7 billion (+59%)
YTD Revenues: $56.1 billion (+6%)
YTD Earnings: $13.8 billion (+34%)
Comments: Worldwide Pharmaceutical sales were $8.3 billion in the quarter, up 18%, with domestic sales up 33%, international sales up 3%, and a negative currency impact of 1%. Sales were driven by new products OLYSIO/SOVRIAD (simeprevir) for chronic hepatitis C; XARELTO (rivaroxaban), an oral anticoagulant; INVOKANA (canagliflozin) for type 2 diabetes; ZYTIGA (abiraterone acetate), for metastatic, castration-resistant prostate cancer; and IMBRUVICA (ibrutinib) for the treatment of several hematologic malignancies. Additional drivers were STELARA (+47% to $543 million), REMICADE (+5% to $1.8 billion), and INVEGA SUSTENNA/XEPLION (+24% to $403 million).
